BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 23, 2005
View Archived Issues
High Number Of Dropouts Spoil Oxytrex Phase III Trial
Shares in Pain Therapeutics Inc. lost nearly 20% of their value on news that a Phase III study of Oxytrex was inadequate due to patient dropouts, meaning another trial is in order. (BioWorld Today)
Read More
Point Therapeutics Offering Gets $22.2M For Talabostat
Read More
Antitrust Hearing Could Lead To Changes In Merger Review
Read More
Nurel, Diamyd Combine GAD Technologies Through Merger
Read More
Holiday Notice
Read More
Other News To Note
Read More